[go: up one dir, main page]

AR124178A1 - Formulación compuesta para administración oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico y un proceso para su preparación - Google Patents

Formulación compuesta para administración oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico y un proceso para su preparación

Info

Publication number
AR124178A1
AR124178A1 ARP210103303A ARP210103303A AR124178A1 AR 124178 A1 AR124178 A1 AR 124178A1 AR P210103303 A ARP210103303 A AR P210103303A AR P210103303 A ARP210103303 A AR P210103303A AR 124178 A1 AR124178 A1 AR 124178A1
Authority
AR
Argentina
Prior art keywords
indol
pyrazole
cyano
isopropyl
carboxylic acid
Prior art date
Application number
ARP210103303A
Other languages
English (en)
Inventor
Seok Cheol Yoo
Sun Lee
Duck Il Yun
Junghong Park
Hyun Ji Sun
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of AR124178A1 publication Critical patent/AR124178A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Reivindicación 1: Una formulación oral estable que comprende un principio farmacéutico activo (API), que es ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico o una sal farmacéuticamente aceptable de este y uno o más excipientes, caracterizada porque la formulación no incluye un estabilizador separado como un excipiente, y donde el 90% en peso o más del API se mantiene a 40ºC y 75% de humedad relativa durante 6 meses, o se mantiene a 80ºC y 75% de humedad relativa durante 12 días o se mantiene a 25ºC y 60% de humedad relativa durante 1 año.
ARP210103303A 2020-12-01 2021-11-30 Formulación compuesta para administración oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico y un proceso para su preparación AR124178A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20200166051 2020-12-01

Publications (1)

Publication Number Publication Date
AR124178A1 true AR124178A1 (es) 2023-02-22

Family

ID=81854222

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210103303A AR124178A1 (es) 2020-12-01 2021-11-30 Formulación compuesta para administración oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico y un proceso para su preparación

Country Status (15)

Country Link
US (1) US20240000751A1 (es)
EP (1) EP4257123A4 (es)
JP (1) JP7678106B2 (es)
KR (1) KR20220077091A (es)
CN (1) CN116528852A (es)
AR (1) AR124178A1 (es)
AU (2) AU2021390901B9 (es)
CA (1) CA3197405A1 (es)
CL (1) CL2023001215A1 (es)
CO (1) CO2023008265A2 (es)
MX (1) MX2023005459A (es)
PE (1) PE20240222A1 (es)
TW (2) TWI896975B (es)
WO (1) WO2022119269A1 (es)
ZA (1) ZA202305156B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117412746A (zh) * 2021-06-15 2024-01-16 株式会社Lg化学 包含1-(3-氰基-1-异丙基-吲哚-5-基)吡唑-4-甲酸的药物组合物
AR126164A1 (es) * 2021-06-17 2023-09-27 Lg Chemical Ltd Formulación compuesta para dosificación oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003257103A1 (en) * 2002-07-31 2004-02-16 Pharmacia Corporation Gelatin capsule exhibiting reduced cross-linking
AU2006206292B2 (en) * 2005-01-21 2009-09-03 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical formulations of zonisamide and methods for their manufacture
US8003647B2 (en) * 2007-04-11 2011-08-23 Kissei Pharmaceutical Co., Ltd. (Aza)indole derivative and use thereof for medical purposes
TWI423962B (zh) * 2009-10-07 2014-01-21 Lg Life Sciences Ltd 有效作為黃嘌呤氧化酶抑制劑之新穎化合物、其製備方法及含該化合物之醫藥組成物
TWI548630B (zh) * 2011-04-06 2016-09-11 Ｌｇ生命科學有限公司 １－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸結晶型及其製造方法
WO2020109319A1 (en) * 2018-11-27 2020-06-04 Zaklady Farmaceutyczne Polpharma S.A Pharmaceutical composition comprising ramipril and indapamide
MY208699A (en) * 2020-11-04 2025-05-25 Lg Chemical Ltd Method for preparing crystalline particles of 1-(3-cyano-1-isopropyl-indole-5-yl)pyrazole-4-carboxylic acid, and pharmaceutical composition comprising same
MX2023005461A (es) * 2020-12-01 2023-05-22 Lg Chemical Ltd Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico y un proceso para su preparacion.
PE20240764A1 (es) * 2021-04-16 2024-04-17 Lg Chemical Ltd Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico

Also Published As

Publication number Publication date
CA3197405A1 (en) 2022-06-09
PE20240222A1 (es) 2024-02-16
US20240000751A1 (en) 2024-01-04
EP4257123A1 (en) 2023-10-11
AU2024227367A1 (en) 2024-10-31
AU2021390901A1 (en) 2023-06-08
MX2023005459A (es) 2023-05-23
CO2023008265A2 (es) 2023-06-30
KR20220077091A (ko) 2022-06-08
CL2023001215A1 (es) 2023-12-15
JP7678106B2 (ja) 2025-05-15
WO2022119269A1 (ko) 2022-06-09
AU2021390901A9 (en) 2024-05-23
TWI896975B (zh) 2025-09-11
JP2023551712A (ja) 2023-12-12
TW202228679A (zh) 2022-08-01
TWI840721B (zh) 2024-05-01
EP4257123A4 (en) 2024-05-08
AU2021390901B9 (en) 2024-11-21
AU2021390901B2 (en) 2024-11-07
CN116528852A (zh) 2023-08-01
TW202408496A (zh) 2024-03-01
ZA202305156B (en) 2024-09-25

Similar Documents

Publication Publication Date Title
MX2024002495A (es) Inhaladores de dosis medida y composiciones en suspension.
AR124178A1 (es) Formulación compuesta para administración oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico y un proceso para su preparación
BR112012030177A2 (pt) composto, uso do mesmo, e, composição farmacêutica
MX378856B (es) Composiciones farmaceuticas parenterales acuosas estables de peptidos insulinotropicos.
EA201490801A1 (ru) Композиции этанерцепта, стабилизированные комбинациями сахаров и полиолов
BR112022009209A2 (pt) Derivado de amida e método de preparação e uso do mesmo na medicina
AR125250A1 (es) Composiciones de psilocibina, procedimientos de fabricación y procedimientos de uso de las mismas
CL2020000625A1 (es) Proceso para formulación farmacéutica liofilizada de una proteína terapéutica.
AR114323A1 (es) Péptidos de la cadena b de la relaxina modificados y su uso terapéutico
UY38068A (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
UY30935A1 (es) Combinacion:-antagonista del receptor de quimioquina 1 (ccr1) -agonista del receptor de glucocorticoides- opcionalmente agonista b(beta)2, -composicion farmacéutica conteniéndola -aplicaciones.
MX2021014830A (es) Conjugados de compuestos que comprenden nitrogeno heteroaromatico donador de pares de electrones pi.
AR125366A1 (es) Formulación compuesta para administración oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico
DOP2023000084A (es) Formulación sólida
CO2022014452A2 (es) Formulaciones líquidas de análogos de glucagón
MX2024010321A (es) Inhibidores de la quinasa tipo polo 4 (plk4), composiciones farmaceuticas, metodos de preparacion y usos de los mismos
MX2024011654A (es) Formulaciones que comprenden melfalan flufenamida y ciclodextrina
MX2021012782A (es) El uso de polivinilpirrolidona (pvp) de bajo peso molecular para reducir la viscosidad de formulaciones de proteinas de alta concentracion.
MX2022005187A (es) Compuesto de ácido oxocarboxílico heterocíclico de cinco miembros y el uso médico del mismo.
CL2022002932A1 (es) Composiciones y métodos para suministrar agentes farmacéuticamente activos
AR129775A1 (es) Composición farmacéutica que contiene agonista del receptor de adenosina a3 para el tratamiento de la psoriasis
CR20220069A (es) Composiciones farmacéuticas resistentes a la descarga de dosis que comprenden venirunad
EA201890789A1 (ru) Содержащая цинеол композиция для лечения заболеваний носа
BR112022024807A2 (pt) Composição farmacêutica aquosa de levilimab, uso e métodos de produção da mesma
BR112022006313A2 (pt) Formulação de suspensão pediátrica